Figure 2.
Figure 2. CD44act is preferentially expressed on CD4CD25+ Treg cells after activation. (A) Absence of CD44act expression on resting CD4CD25+ and CD4CD25– T cells. (B) Kinetics of activation marker expression on CD25+ and CD25– CD4 T cells. CD4 cells were separated into CD4CD25+ and CD4CD25– fractions and activated at 1 × 106 cells/well with increasing concentrations of plate-bound anti-CD3 with (open) or without (closed) 5 μg/mL anti-CD28. The percentage of CD69+ cells (top) and blast-positive cells (by scatter, middle) are nearly indistinguishable between populations, whereas the percentage of Fl-HA–binding cells differs significantly between CD4CD25+ and CD4CD25– for both treatments (bottom; P ≤ .01, Wilcoxon test). (C) CD44act expression on CD4CD25+ versus CD4CD25– cells after 18-, 42-, and 72-hour activation with 5 μg/mL plate-bound anti-CD3/anti-CD28. Data shown are the mean ± SD from 3 independent experiments (*P ≤ .001; **P ≤ .01). FACS analyses from a representative experiment are shown below for the 18-hour time point with and without the HA-blocking anti-CD44 antibody, KM81.

CD44act is preferentially expressed on CD4CD25+ Treg cells after activation. (A) Absence of CD44act expression on resting CD4CD25+ and CD4CD25 T cells. (B) Kinetics of activation marker expression on CD25+ and CD25 CD4 T cells. CD4 cells were separated into CD4CD25+ and CD4CD25 fractions and activated at 1 × 106 cells/well with increasing concentrations of plate-bound anti-CD3 with (open) or without (closed) 5 μg/mL anti-CD28. The percentage of CD69+ cells (top) and blast-positive cells (by scatter, middle) are nearly indistinguishable between populations, whereas the percentage of Fl-HA–binding cells differs significantly between CD4CD25+ and CD4CD25 for both treatments (bottom; P ≤ .01, Wilcoxon test). (C) CD44act expression on CD4CD25+ versus CD4CD25 cells after 18-, 42-, and 72-hour activation with 5 μg/mL plate-bound anti-CD3/anti-CD28. Data shown are the mean ± SD from 3 independent experiments (*P ≤ .001; **P ≤ .01). FACS analyses from a representative experiment are shown below for the 18-hour time point with and without the HA-blocking anti-CD44 antibody, KM81.

Close Modal

or Create an Account

Close Modal
Close Modal